세계의 기관지 확장제 시장 규모 : 약품 클래스, 투여경로, 용도, 유통채널, 최종용도별 예측

Bronchodilators market size will register a 4.9% CAGR between 2024 and 2032 driven by the increasing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis globally. As per WHO, approximately 392 million people are estimated to be living with COPD. With these conditions continuing to escalate due to factors like air pollution, smoking, and aging populations, there is growing demand for effective medications that can alleviate symptoms and improve the quality of life for patients.

Technological advancements in inhalation devices and formulations are expanding the accessibility and efficacy of bronchodilator treatments. Innovations in dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers are offering patients more convenient and precise delivery methods for bronchodilator medications. The ongoing R&D efforts focused on developing novel bronchodilator therapies with improved safety profiles and longer-lasting effects will further drive the market growth.

The overall industry is classified into drug-class, route of administration, application, distribution channel, end-use, and region.

Based on drug class, the bronchodilators market size from the xanthine segment is slated to record a strong growth rate through 2032 due to its established efficacy in managing chronic respiratory conditions like asthma and COPD. Xanthine derivatives, such as theophylline, work by relaxing the smooth muscles in airways to improve airflow and reducing symptoms, such as wheezing and shortness of breath. These medications are also used as maintenance therapy to control symptoms and prevent exacerbations in patients.

Bronchodilators market from the asthma application segment is projected to observe a substantial CAGR during 2024-2032 owing to its increasing prevalence worldwide. Bronchodilators help in managing asthma symptoms by relaxing the muscles around the airways to improve airflow and alleviate acute breathing difficulties. As healthcare systems focus on improving asthma management and reducing hospitalizations, the demand for effective bronchodilator medications tailored to asthma treatment will continue to rise.

Asia Pacific bronchodilators industry will witness a robust growth rate between 2024 and 2032. Rapid urbanization and industrialization in countries like China and India are making way for higher levels of air pollution, leading to greater incidence of respiratory conditions. This is driving the need for effective treatment options. Governments are also focusing on improving respiratory disease management through awareness campaigns and healthcare reforms, further boosting the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory disorders such as asthma and COPD
    • 3.2.1.2 Ongoing R&D efforts and new product approvals
    • 3.2.1.3 Off-label use of bronchodilators
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug-class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Beta-adrenergic bronchodilators
• 5.3 Anticholinergic bronchodilators
• 5.4 Xanthine derivatives
• 5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable
• 6.4 Inhaled
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Asthma
• 7.3 Chronic obstructive pulmonary disease (COPD)
• 7.4 Other application

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Specialty clinics
• 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AstraZeneca
• 11.2 Boehringer Ingelheim International GmbH
• 11.3 Cipla Inc.
• 11.4 GlaxoSmithKline plc
• 11.5 Glenmark Pharmaceuticals Limited
• 11.6 Innoviva
• 11.7 Medline Plus
• 11.8 Merck & Co.,
• 11.9 Mylan N.V.
• 11.10 Novartis AG
• 11.11 Sun Pharmaceutical Industries Ltd
• 11.12 Teva Pharmaceutical Industries Ltd